ArticleWorld journal of gastrointestinal pharmacology and therapeutics2025
Comorbidities and systemic steroids drive pneumonia risk in inflammatory bowel disease: Propensity score-matched cohort study.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing data quality of inflammatory bowel disease patients in theJAMIA open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with inflammatory bowel disease (IBD) are at an increased risk of bacterial pneumonia, contributing to significant morbidity and mortality. While previous studies have identified various risk factors, including medications and comorbidities, the independent contribution of IBD to pneumonia risk remains unclear. We hypothesized that the increased pneumonia risk is primarily driven by factors other than IBD itself.
aimTo investigate the relative contributions of IBD, comorbidities, and medications to pneumonia risk in patients with IBD.
methodsWe conducted a retrospective cohort study using the All of Us Research Program database (2010-2022). We matched 2810 participants with IBD 1:1 with controls using four propensity score models: (1) Demographics/Lifestyle only; (2) Plus comorbidities; (3) Plus medications; and (4) All factors combined. Then we used Cox proportional hazards models to assess pneumonia risk and logistic regression to evaluate risk factors.
resultsIn the primary analysis of 5620 matched participants, IBD was not independently associated with increased pneumonia risk [hazard ratio (HR) = 1.07, 95%CI: 0.84-1.35] when matched for all factors. However, participants with IBD had significantly higher risk (HR = 2.08, 95%CI: 1.56-2.78) when matched only for demographics and lifestyle factors. Within the IBD cohort, a high comorbidity burden (Charlson Comorbidity Index ≥ 10) [odds ratio (OR) = 12.20, 95%CI: 6.69-23.00] and systemic steroid use (OR = 2.26, 95%CI: 1.21-4.64) were independently associated with increased pneumonia risk.
conclusionComorbidities and systemic steroids, rather than IBD itself, drive pneumonia risk. Management should focus on these factors and prioritize vaccination in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.